2. Search Result
Search Result
Results for "

thromboxane+synthase

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Biochemical Assay Reagents

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-106961
    ONO 1301

    ONO-AP 500-02

    		 Prostaglandin Receptor Cardiovascular Disease
    ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
    ONO 1301
  • HY-106961A
    (Z)-ONO 1301

    (Z)-ONO-AP 500-02

    		 Prostaglandin Receptor Cardiovascular Disease
    (Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
    (Z)-ONO 1301
  • HY-113445
    Thromboxane B3

    		COX Endogenous Metabolite Endocrinology
    Thromboxane B3 is a prostaglandin analog derived from arachidonic acid (AA) in the cyclooxygenase (COX) metabolic pathway. Thromboxane B3 is generated from arachidonic acid (AA) in platelets and vascular endothelial cells through the catalysis of cyclooxygenase (COX) and thromboxane synthase (TXS). Thromboxane B3 has been reported to be formed by human platelets upon ingestion of eicosapentaenoic acid (C20: 5ω3) .
    Thromboxane B3
  • HY-135447
    BM-531

    		Prostaglandin Receptor Others
    BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED100 of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED50 of 0.482 μM. BM-531 inhibits high-K +-induced contraction of porcine uterine smooth muscle .
    BM-531
  • HY-105193
    E 3040

    		Lipoxygenase Prostaglandin Receptor Inflammation/Immunology
    E 3040 is an orally active dual inhibitor of 5-lipoxygenase and thromboxane synthase. E 3040 exhibits anti-inflammatory effect .
    E 3040
  • HY-105866
    Wy 27569

    		Calcium Channel Prostaglandin Receptor Cardiovascular Disease
    Wy 27569 is an orally active vascular selective calcium channel blocker that can effectively lower blood pressure. Wy 27569 is a thromboxane synthase inhibitor that can reshape prostaglandin balance, reduce pro thrombotic TXA2, and increase anti thrombotic PGI2. Wy 27569 can be used for research on cardiovascular diseases such as hypertension and angina .
    Wy 27569
  • HY-165587
    BM-573

    		Prostaglandin Receptor Cardiovascular Disease
    BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC50 of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .
    BM-573
  • HY-105114
    Imitrodast

    		Prostaglandin Receptor Inflammation/Immunology
    Imitrodast is an inhibitor of thromboxane synthase. Imitrodast can be used in the research of bronchoconstriction .
    Imitrodast
  • HY-106119
    Camonagrel

    		Prostaglandin Receptor Infection
    Camonagrel is a compound that has inhibitory effects on Prostaglandin E2. Camonagrel is a potent thromboxane synthase inhibitor .
    Camonagrel
  • HY-118765
    Ro 23-3423

    		Prostaglandin Receptor Cardiovascular Disease
    Ro 23-3423 is a thromboxane synthase inhibitor with an IC50 value of 0.33 μM for human platelet microsomal thromboxane synthase. Ro 23-3423 increases plasma levels of PGF and PGE2 in a dose-dependent manner, accompanied by a decrease in mean systemic arterial pressure and systemic vascular resistance. Ro 23-3423 can be used in the study of general anesthesia .
    Ro 23-3423
  • HY-117019
    LY150310 free base

    		COX Cancer
    LY150310 inhibits thromboxane synthase, cyclooxygenase, and thrombin activation. LY150310 inhibits spontaneous lung metastasis in a dose-dependent manner.
    LY150310 free base
  • HY-106080A
    Furegrelate sodium

    U-63557A

    		 Prostaglandin Receptor Cardiovascular Disease
    Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
    Furegrelate sodium
  • HY-106080
    Furegrelate

    U-63557A free acid

    		 Prostaglandin Receptor Cardiovascular Disease
    Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent .
    Furegrelate
  • HY-106080AR
    Furegrelate sodium (Standard)

    U-63557A (Standard)

    		 Prostaglandin Receptor Reference Standards Cardiovascular Disease
    Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
    Furegrelate sodium (Standard)
  • HY-137227
    15(R)-PTA2

    15(R)-Pinanethromboxane A2

    		 Prostaglandin Receptor Cardiovascular Disease
    15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .
    15(R)-PTA2
  • HY-106961R
    ONO 1301 (Standard)

    ONO-AP 500-02 (Standard)

    		 Reference Standards Prostaglandin Receptor Cardiovascular Disease
    ONO 1301 (Standard) (ONO-AP 500-02 (Standard)) is the analytical standard of ONO 1301 (HY-106961). This product is intended for research and analytical applications. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
    ONO 1301 (Standard)
  • HY-105265
    Rolafagrel

    FCE 22178

    		 Prostaglandin Receptor Cardiovascular Disease
    Rolafagrel is an inhibitor of thromboxane synthase. Rolafagrel can be studied in cardiovascular research .
    Rolafagrel
  • HY-105114A
    Imitrodast sodium

    CS-518

    		 Prostaglandin Receptor Inflammation/Immunology
    Imitrodast sodium is an inhibitor of thromboxane synthase. Imitrodast sodium can be used in the research of bronchoconstriction .
    Imitrodast sodium
  • HY-106398
    MED 27

    		Prostaglandin Receptor Cardiovascular Disease
    MED 27 is an inhibitor of thromboxane synthase and thromboxane A2 receptors. MED 27 can inhibit rat platelet aggregation at doses much lower than that of Acetylsalicylic acid (HY-14654) .
    MED 27

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: